Antibodies in Systemic Scleroderma

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
ANCA and Anti-PR3
DNA, Topoisomerase I
ESR (Sed Rate)
PmScl and dsDNA
TNF and IL-13

Overview of Antibodies in Systemic Scleroderma

Abstract PaintingDozens of antibodies can occur in systemic scleroderma patients. They can be useful for diagnosing, categorizing and predicting the likelihood of certain complications.

However, scleroderma is always a clinical diagnosis, which means that it is based upon symptoms and not bloodwork. This is because some people with scleroderma never develop antibodies, and also because entirely healthy people can have antibodies but never develop scleroderma or any other autoimmune disease. (Also see Overview of Antibodies, What is Scleroderma?, Types of Scleroderma and Systemic Symptoms)

Disease–related autoantibody (autoABs) profile in patients with systemic sclerosis (SSc). Anti-Topo I, anti-CENP, and anti-RNA pol III are the most prevalent autoAbs in SSc. PubMed, Autoimmunity, 2017 Jul 27:1-8.

New tools can potentially play key role in early diagnosis of systemic sclerosis. The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools. News Medical, 06/14/2017. (Also see Nailfold Capillaroscopy)

Antibodies That Attack Inflammatory Immune Cells May Work to Treat Scleroderma. Antibodies against a protein selectively expressed on certain types of immune system cells were seen to prevented fibrosis in rodent models of scleroderma and lung fibrosis. Scleroderma News, 09/27/2016.

Autoantibodies Present in Scleroderma, Myositis Explored in New Review. These specific autoantibodies play a role in muscle damage, their detection in an early disease stage may help predict the disease course and prognosis. Scleroderma News, 05/27/2015.

Examination of autoantibody status and clinical features that associate with cancer risk and cancer-associated scleroderma. Increased age at scleroderma onset is strongly associated with cancer risk overall. PubMed, Arthritis Rheumatol, 01/20/2015. (Also see Cancer and Scleroderma)

Novel autoantibodies in inflammatory myopathies and systemic sclerosis. The scope of this article is to review the diagnostic and prognostic value of antibodies in inflammatory myopathies and systemic sclerosis. PubMed, Rev Med Suisse, 2015 Jan 14;11(456-457):25-9. (Also see Myopathy and Myositis)

Early systemic sclerosis (SSc): Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. The data demonstrate faster progression of SSc in autoantibody–positive patients, particularly in those with preclinical internal organ involvement at baseline, than in autoantibody–negative patients. PubMed, Arthritis Care Res (Hoboken), 2014 Feb 10. (Also see Capillaroscopy)

ACA: Anticentromere Antibodies

The limited cutaneous form of systemic sclerosis (SSc) is associated with urinary incontinence (UI): an international multicentre study. Self–reported UI is frequent in SSc and disproportionally affects the limited cutaneous form of the disease and patients positive for Anticentromere Antibodies. PubMed, Rheumatology (Oxford), 08/01/2017. (Also see Interstitial Cystitis)

Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy (NVC) patterns and disease–specific autoantibodies. All SSc–specific auto–antibodies were found, with ACA and anti-Scl-70 being the most prevalent and the association between NVC–pattern and heart/lung involvement was independent of specific anti-ENA antibodies, which might indicate microangiopathy is an important cause of organ involvement. PubMed, Rheumatology (Oxford), 12/10/2016. (Also see Nailfold Videocapillaroscopy and Scleroderma Cardiac (Heart) Involvement)

Increased risk of digital vascular events in scleroderma patients who have both anti–centromere (CENP) and anti–nterferon–inducible protein 16 (IF–16) antibodies. This study provides further evidence that anti–CENP and anti–IFI–16 antibodies are disease biomarkers that may be used for risk stratification of vascular events in scleroderma. PubMed, Arthritis Care Res (Hoboken), 07/07/2016. (Also see Prognosis and Mortality)

Anti-centromere protein A antibodies in systemic sclerosis (SSc): Significance and origin. Preliminary evidence for a possible role of forkhead box protein E3 in SSc pathogenesis is discussed and for the association of different subsets of anti-CENP-A antibodies. PubMed, Autoimmun Rev, 10/09/2015.

Serology Helps Pinpoint Type of Scleroderma. Serologic status should be added to extent of skin involvement for more accurate classification of disease phenotype in systemic sclerosis. Medpage Today, 04/23/2015.

Impact of anti-centromere antibodies (ACA) on pulmonary function test (PFT) results in patients with systemic sclerosis without established or suspected pulmonary disease. Patients with ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. PubMed, Clin Rheumatol, 2014 Apr 22. (Also see Pulmonary Hypertension Diagnosis)

Centromere Antibody, IgG. Centromere antibody is present in 80-90% of individuals with CREST variant scleroderma. This antibody is also seen in 30% of Raynaud patients, 12% of patients with mixed connective-tissue disease, diffuse scleroderma, interstitial pulmonary fibrosis, primary biliary cirrhosis, and in a smaller percent of patients with systemic lupus erythematosus (SLE) and RA. ARUP Laboratories.

AECA: Agonistic anti-ICAM-1 Antibodies

Agonistic anti-ICAM-1 antibodies in scleroderma (SSc): Activation of endothelial pro-inflammatory cascades. Anti-endothelial cell antibodies (AECA) from SSc patients target specific endothelial antigens including ICAM-1, and cause pro-inflammatory activation of human endothelial cells, suggesting that they are not only a marker of disease but that they contribute to its progression. PubMed, Vascul Pharmacol. (Also see Causes of Scleroderma: Endothelin)

AFA: Antifibroblast Antibodies

Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. These antibodies identify a subgroup of patients with SN in whom an underlying autoimmune disorder affecting sensory neurons in the dorsal root and trigeminal nerve ganglia is suspected. PubMed, J Neurol Neurosurg Psychiatry, 2015 Jan 27.

ANA: Antinuclear Antibodies

Definition of Antinuclear antibody. Antinuclear antibodies (ANAs) are found in patients whose immune system is predisposed to cause inflammation against their own body tissues.

Circulating Anti–Nuclear Antibodies (ANA) in Systemic Sclerosis (SSc): Utility in Diagnosis and Disease Subsetting. Since these autoantibodies are specifically detected in SSc patients they are widely used in routine clinical practice for diagnosis, clinical subgrouping, and prediction of future organ involvements and prognosis. PubMed, J Nippon Med Sch, 2017;84(2):56-63.

Scleroderma ANA and Antibody Testing Basics This technical article, which has just been updated, discusses issues related to ANA and antibody testing for patients that have or might have Scleroderma and is one of the "ANA and Antibody Series" by The Scleroderma Education Project., 03/19/2017.

Antinuclear antibody negative systemic sclerosis. SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy, a greater proportion of males and possibly, more frequent lower gastrointestinal involvement. Seminars in Arthritis and Rheumatism, 11/28/2014.

ANCA and Anti-PR3

Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis. Antibody specificity changes in AAV are rareand monitoring only the initial antibody specificity would have missed clinical events but rising C–reactive protein presaged relapse in these cases. PubMed, Ann Clin Biochem, 2015 Mar;52(Pt 2):297-301.

ANoA: Antinucleolar Antibodies

A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Our new method readily detects these two clinically important antibodies in SSc. Making tests for anti-Th/To and -U3RNP antibodies widely available to clinicians should be helpful in the diagnosis and follow-up of SSc patients. Arthritis Research and Therapy.

APA: Antiphospholipid Antibodies

Antiphospholipid Antibodies (APS) and Systemic Scleroderma. APS is being increasingly recognized as an important cause of renal damage due to thrombosis at any location within the renal vasculature. Turk J Haematol.

AT1R and ETAR Antibodies

Angiotensin receptor type 1 (AT1R) and endothelin receptor type A (ETAR) on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis (SSc) patients. PubMed, Arthritis Res Ther, 2014 Mar 11;16(2):R65. (Also see Causes of Scleroderma: Endothelin)

BPI Antibodies

BPI Antibodies: Bactericidal/Permeability-Increasing Protein and Cathepsin G Are the Major Antigenic Targets of Antineutrophil Cytoplasmic Autoantibodies in Systemic Sclerosis. The study included 33 patients with diffuse and 35 with limited SSc. Patients with antibodies to BPI (bactericidal/permeability-increasing protein) had lower skin scores. J Rheumatol.

Caspase-3 Antibody

Autoantibody (Ab) against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis (SSc). These results suggest that autoantibody against caspase-3 is generated in SSc and that this Ab is related to the severity of pulmonary fibrosis, vascular damage, and inflammation. Shihoko Okazaki (SpringerLink) Rheumatology International.

CCP: Anti-Cyclic Citrullinated Peptide Antibodies

Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. Anti-CCP are a hallmark of RA, but may be observed in other inflammatory, systemic, or mechanical diseases. PubMed, J Rheumatol, 2014 Dec;41(12):2395-402.

CRP: C-Reactive Protein

Being Bullied Is Bad for Your Health. Being bullied raises the blood's level of C-Reactive Protein or CRP a marker of systemic inflammation and a risk factor for cardiovascular and other diseases. New York Times, 05/12/2014.

DNA: Anti-DNA and Anti-Topoisomerase I Antibodies

Clinical differences between Thai systemic sclerosis (SSc) patients with positive versus negative anti-topoisomerase l (ATA). A high prevalence of ATA positivity was found among Thai SSc patients and this was associated with a high frequency of hand deformity, anti-centromere negativity, a short duration of pulmonary fibrosis in Diffuse SSc and a lower frequency of Raynaud's phenomenon in Limited SSc. PubMed, Int J Rheum Dis, 10/08/2014.


Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Eosinophilia can be seen in various rheumatologic conditions but, as corticosteroids are one of the most common medications used in collagen tissue diseases, the eosinophil numbers found may be lower than expected and eosinophilia may be more frequent than reported. PubMed, Rheumatol Int.

IgA Antibodies

Reversible IgA deficiency after severe Gram-negative bacteria infection in a patient with systemic sclerosis. Although the mechanism of secondary IgAD is still vague, its association with autoimmune diseases including SSc and also with bacterial infection is discussed. (Springerlink) Masato Yagita. (Also see Bacterial Infections)

IgG Antibodies

Immunoglobulins. Antibodies attach to the foreign substances so the immune system can destroy them.IgG antibodies are found in all body fluids. They are the smallest but most common antibody (75% to 80%) of all the antibodies in the body. WebMD.

Epitope specificity determines pathogenicity and detectability of anti-PDGFRa autoantibodies in systemic sclerosis. Agonistic anti-PDGFRa autoantibodies are enriched in SSc sera and recognize specific conformational epitopes, that can be used to discriminate agonistic from nonagonistic antibodies and block PDGFRa signaling in SSc. PubMed, Arthritis Rheumatol, 03/25/2015.


Immunodeficiency disorders. Immunodeficiency disorders occur when the body's immune response is reduced or absent. When the immune system detects an antigen, it responds by producing proteins called antibodies that destroy the harmful substances. MedlinePlus.

KU: Anti-KU Antibodies

Single–specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis (SSc) subjects: clinical associations. This is the largest cohort to date focusing on the prevalence and disease characteristics of single–specificity anti-Ku antibodies in subjects with SSc. PubMed, Medicine (Baltimore). 2016 Aug;95(35):e4713. (Also see Ethnicity, Race and Geographical Regions)

LPL: Anti-lipoprotein Lipase Antibody

Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. The presence of IgG anti-LPL antibody was associated with elevated serum triglyceride levels, greater extent of skin fibrosis, and more frequent presence of lung fibrosis, heart involvement, and anti-topoisomerase I antibodies. J Rheumatol.


CD57 in human natural killer cells and T-lymphocytes. Functional modulation of senescent CD57(pos) T-cells and mature CD57(pos) NK cells may therefore represent innovative strategies for protection against human immunological aging and/or various chronic diseases. PubMed, Cancer Immunol Immunother, 2016 Apr;65(4):441-52. (Also see Natural Killer Cells)

MMP-3 Antibodies

Matrix metalloproteinase (MMP) gene polymorphisms and susceptibility to systemic sclerosis. These results suggest that MMP polymorphisms are not associated with SSc susceptibility, although MMP1 and MMP3 variants are associated with specific SSc clinical and laboratory features. PubMed, Genet Mol Res, 2016 Dec 19;15(4).

Cysteine-rich 61 (Cyr61) participates in the pathogenesis of rheumatoid arthritis (RA) via promoting MMP-3 expression by fibroblast-like synoviocytes. This study provides new evidence that Cyr61 participates in RA pathogenesis not only as a pro–inflammatory factor but also plays a key role in bone erosion via promoting MMP-3 expression. PubMed, Mod Rheumatol, 2016 Sep 1:1-10. (Also see Treatments for Rheumatoid Arthritis)

Nucleolar Antibodies

Antinuclear antibody–negative systemic sclerosis (SSc). The results of this study suggest that SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy, a greater proportion of males, and possibly, more frequent lower gastrointestinal involvement. PubMed, Semin Arthritis Rheum, 2015 Jun;44(6):680-6.

PM/Scl: Anti-PM/SCL-100

Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma (SSc). In Japanese patients, anti-PM/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc. PubMed, Arthritis Res Ther, 2015 Mar 11;17:57. (Also see Ethnicity, Race and Geographical Regions)

PmScl and dsDNA

Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Several features and prognosis of ILD in SSc may be modified depending on the identified immunological profile. Seminars in Arthritis and Rheumatism, 07/15/2014. (Also see Pulmonary Fibrosis Prognosis)

RNA-Polymerases Antibodies

Cancers associated with systemic sclerosis (SSc) involving anti-RNA polymerase III antibodies. Anti-RNA polymerase III antibodies are useful for SSc diagnosis in patients without anti-centromere or anti-Scl70 antibodies and their presence must lead physicians to screen for associated cancer, even in the absence of clinical signs. PubMed, Ann Dermatol Venereol, 09/13/2017. (Also see Cancer)

Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Strong evidence was found for both intra and intermolecular epitope spreading in patients with RNA polymerase III (POLR3) and the minor spliceosome specificities. PNAS, 11/07/2016.

Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA (miRNA) in systemic sclerosis. Circulating miRNA profiles differ between limited and diffuse scleroderma patients and between patients with different autoantibodies. PubMed, Rheumatology (Oxford), 07/10/2015.

Demographic and clinical features of systemic sclerosis (SSc) patients with anti-RNA polymerase III antibodies (RNAP). Measurement of RNAP in SSc patients is useful for the diagnosis and risk stratification of severe manifestation, such as renal crisis and severe skin sclerosis. PubMed, J Dermatol, 12/06/2014.

Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis. Geographic factors were significantly associated with prevalence, which underscores the probable implication that genetic background and environmental factors play a role. PubMed, Arthritis Rheumatol, 2014 Feb;66(2):407-17. (Also see Ethnicity, Race and Geographical Regions)

SCL-70 Antibodies

Analysis of anti-topoisomerase I antibodies (Abs) in patients with systemic sclerosis before and after autologous stem cell transplantation (aSCTrans). The presence of anti-topo489-573 Abs before aSCTrans may indicate a less favourable course after aSCTrans. PubMed, Rheumatology (Oxford), 12/10/2016. (Also see Stem Cell Transplantation)

Oral manifestations of Systemic Sclerosis and Correlation with anti-Topoisomerase I Antibodies (SCL-70). Oral symptoms have been frequent in patients with Scleroderma, SCL -70 positive but not statistically significant difference. PubMed, Med Arch, 2015 Jun;69(3):153-6. (Also see Dental Involvement)

TAA: Tumor-associated antigens

Tumor-associated antigens (TAAs) in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices. The production of some TAAs may also be increased in patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and other connective tissue diseases. E Szekanecz. PubMed, Journal of Autoimmunity.

TNF and IL-13: Tumor Necrosis Factor and Interleukin-13

Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis? Our preliminary results suggest increased serum a proliferation-inducing ligand (APRIL) levels in systemic sclerosis patients, particularly in those associated with myositis and hypergammaglobinemia. IS Bassyouni. Joint Bone Spine. (Also see Tumor Necrosis Factor)

Go to Autoimmune Antibodies

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.